Pharma Capital
Why invest in THC?

The Hydroponics Company Ltd granted a cannabis research licence

The licence allows Canndeo to build its exclusive Plant Breeders Rights.
The Hydroponics Company Ltd issued a cannabis research licence
BigPicture
Dr Andrew Beehag, CEO of Canndeo, recently presenting to investors

The Hydroponics Company (ASX:THC) is one of the first ASX-listed cannabis companies to have secured a medicinal cannabis research licence.

The license was granted to THC’s wholly owned subsidiary Canndeo Ltd by the Office of Drug Control.

The research licence will allow Canndeo to build its exclusive Plant Breeders Rights (PBR) protected Cannabis sativa strains.

Dr Andrew Beehag, chief executive officer of Canndeo, commented:

"We are very pleased to have been issued a research licence, which effectively paves the way forward for future domestic supply of medicinal cannabis, targeting multiple markets with high purity cannabidiol (CBD) and enabling THC to continue its roll out of high quality imported products as well as locally produced medicines."


Analysis

THC will now advance research into medicinal cannabis to undertake both its own research exploring optimal cultivation and production methodologies and strain development.

The company will also look to the implementation of its epigenetic technology as a key innovation in the field.

The research licence is the first step in establishing Canndeo’s domestic pharmaceutical production capability with anticipated product availability in 2018.

THC has been one of the most successful IPO's of 2017, and shares are expected to open higher today.

The heavily oversubscribed IPO was priced at $0.20 per share, with the company last trading at $0.31 per share.



Register here to be notified of future THC Company articles
View full THC profile

The Hydroponics Company Ltd Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.